Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Program for Mepolizumab in Hypereosinophilic Syndrome
2024-515247-28-00Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Started Mar 2019; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2024-515247-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515247-28-00.